Analysts Offer Insights on Healthcare Companies: Tonix Pharma (TNXP), Alumis Inc. (ALMS) and Boston Scientific (BSX)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tonix Pharma (TNXP), Alumis Inc. (ALMS) and Boston Scientific (BSX) with bullish sentiments.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tonix Pharma (TNXP)
In a report released today, James Molloy from Alliance Global Partners reiterated a Buy rating on Tonix Pharma, with a price target of $65.00. The company’s shares closed last Friday at $12.88, close to its 52-week low of $6.76.
According to TipRanks.com, Molloy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tonix Pharma with a $51.00 average price target, implying a 275.8% upside from current levels. In a report issued on March 16, Noble Financial also reiterated a Buy rating on the stock with a $37.00 price target.
See today’s best-performing stocks on TipRanks >>
Alumis Inc. (ALMS)
Oppenheimer analyst Jeff Jones reiterated a Buy rating on Alumis Inc. today and set a price target of $55.00. The company’s shares closed last Friday at $24.80.
According to TipRanks.com, Jones is a 5-star analyst with an average return of
Alumis Inc. has an analyst consensus of Strong Buy, with a price target consensus of $38.78, a 49.1% upside from current levels. In a report issued on March 20, Chardan Capital also maintained a Buy rating on the stock with a $38.00 price target.
Boston Scientific (BSX)
In a report released today, Richard Newitter from Truist Financial maintained a Buy rating on Boston Scientific. The company’s shares closed last Friday at $69.17, close to its 52-week low of $66.80.
According to TipRanks.com, Newitter is a 4-star analyst with an average return of
Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $105.14, implying a 50.1% upside from current levels. In a report issued on March 20, Needham also maintained a Buy rating on the stock with a $97.00 price target.
Read More on TNXP:
